It's our mission to improve patients' quality of life and reduce healthcare costs by developing biomarkers in life-threatening diseases
Coretag introduces the first platform technology
targeting necrosis in living human
Our radioligand therapeutics and radioligand diagnostics have the potential to fulfill high unmet medical needs in a wide range of medical conditions that involve necrosis (e.g. cancer, stroke, myocardial infarction, chronic wounds).
Despite the high medical need, sofar there is no tool available in the clinic that can detect, visualize and measure necrosis in living human beings. Coretag has developed and patented a platform technology which offers the possibilty for the development of a range of therapeutic and diagnostic radioligands.
Our first application, NC-Scan (Necrotic Cell Scan) meets a high unmet medical need to determine chemotherapy efficacy.
Up to 65% of chemotherapy for solid tumors is ineffective. But efficacy can only be determined after 3-7 chemotherapy courses. NC-Scan visualizes all types of necrosis in living tissue within 24-36 hours of administration, including cancer therapy-induced necrosis (destroyed cancer cells).
Thanks to this technique, many people with cancer do not have to undergo many chemotherapy courses – up to 9 months sometimes – that later turn out to have been ineffective. Thereby NC-Scan will prevent up to 65% adverse effects which are all for nothing.
Strokes and heart attacks
Our platform technology for targeting necrosis has the potential to meet a wide still unmet medical need in a wide range of medical conditions involving necrosis - such as strokes and heart attacks. Coretag's first product is related to cancer.
Why we first focus on cancer
Cancer is one of the leading causes of death in the world and is responsible for an estimated 9.6 million deaths in 2018 with an increasing number of newly diagnosed cases reaching 15 million in 2020.
NC-Scan as a diagnostic tool
Coretag, in close collaboration with research groups from different cancer centers, is focusing on demonstrating the efficacy of chemotherapy in solid tumors, with a technique called the NC-Scan (necrotic cell-scan). FDA and EMA approval of NC-Scan as a diagnostic tool is expected within 40 months of start.
After seven years of extensive pre-clinical research by various internationally recognized cancer institutions and the filing four patents, Coretag’s NC-Scan is now ready to enter the clinical phase.
Coretag's origin and possibilities
Coretag has its origins in recognized cancer centers in the Netherlands, such as the Leiden University Medical Center and Erasmus Medical Center, Rotterdam. In 2019, Coretag set up its headquarters in Basel, Switzerland with branch offices in Rotterdam, the Netherlands and Boston, MA, USA for coming clinical research.
Endless possibilities; Coretag is working on a broad pipeline development program
The platform technology to target necrotic cells in humans has the potential to result in both radioligand diagnostics and radioligand therapeutics. Coretag is working on a broad pipeline development program. For the first EMA/FDA registration, Coretag focuses on developing the NC-Scan for the visualization of chemotherapy efficacy.
We strive to launch an international pipeline of production development that makes a difference to patients by improving current diagnostics and therapy of major life-threatening diseases.